{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:40Z","timestamp":1791347320661,"version":"4.3.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,15]]},"DOI":"10.1093\/cid\/cit246","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T01:26:46Z","timestamp":1366162006000},"page":"586-593","source":"Crossref","is-referenced-by-count":58,"title":["Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study"],"prefix":"10.1093","volume":"57","author":[{"given":"Anne F.","family":"Luetkemeyer","sequence":"first","affiliation":[{"name":"HIV\/AIDS Division, San Francisco General Hospital, University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene","family":"Lu","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Marzan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Hogg","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc., Silver Spring, Maryland,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance A.","family":"Benson","sequence":"additional","affiliation":[{"name":"Antiviral Research Center, University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Fundacao Oswaldo Cruz, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Sanne","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane V.","family":"Havlir","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Division, San Francisco General Hospital, University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Adult AIDS Clinical Trials Group A5221 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,16]]},"reference":[{"key":"key\n\t\t\t\t20180328171152_CIT246C1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328171152_CIT246C2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"Havlir","year":"2011","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20180328171152_CIT246C3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328171152_CIT246C4","volume-title":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders","author":"World Health Organization","year":"2012"},{"key":"key\n\t\t\t\t20180328171152_CIT246C5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328171152_CIT246C6","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa","volume":"14","author":"Cohen","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328171152_CIT246C8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t20180328171152_CIT246C9","article-title":"Genome wide association study (GWAS) of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group (ACTG) protocols","author":"Grady","year":"2012"},{"key":"key\n\t\t\t\t20180328171152_CIT246C10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/QAD.0b013e32830163ad","article-title":"Clinical impact of patient population differences and genomic variation in efavirenz therapy","volume":"22","author":"King","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","article-title":"CYP2B6 (c.516G\u2013>T) and CYP2A6 (*9B and\/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients","volume":"67","author":"Kwara","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328171152_CIT246C12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","article-title":"CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India","volume":"53","author":"Ramachandran","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180328171152_CIT246C13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.FP0040296","article-title":"Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities","volume":"96","author":"Nishimura","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"key\n\t\t\t\t20180328171152_CIT246C14","article-title":"Identification of isoniazid as a potent inhibitor of CYP2A6-mediated efavirenz 7-hydroxylation in CYP2B6*6 GENOTYPED HUMAN LIVER MICROSOMES","author":"Court","year":"2013"},{"key":"key\n\t\t\t\t20180328171152_CIT246C15","article-title":"Differential induction of efavirenz metabolism by rifampin without and with isoniazid in healthy volunteers with CYP2B6 516GG and TT genotypes","author":"Lee","year":"2013"},{"key":"key\n\t\t\t\t20180328171152_CIT246C16","author":"Efavirenz package insert"},{"key":"key\n\t\t\t\t20180328171152_CIT246C17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20180328171152_CIT246C18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5414\/CP201473","article-title":"Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers","volume":"49","author":"Yenny","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328171152_CIT246C19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0b013e31819c33a3","article-title":"Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis","volume":"50","author":"Ren","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328171152_CIT246C20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","article-title":"Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy","volume":"25","author":"Kwara","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","article-title":"The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis","volume":"68","author":"Gengiah","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180328171152_CIT246C22","volume-title":"Sustiva labeling update\/dosing adjustment with rifampin","author":"Food and Drug Administration"},{"key":"key\n\t\t\t\t20180328171152_CIT246C23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2011.00954.x","article-title":"British HIV Association guidelines for the treatment of TB\/HIV coinfection 2011","volume":"12","author":"Pozniak","year":"2011","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328171152_CIT246C24","article-title":"Antiretroviral therapy for HIV infection in adults and adolescents","volume-title":"Recommendations for a public health approach: 2010 revision","author":"World Health Organization","year":"2010"},{"key":"key\n\t\t\t\t20180328171152_CIT246C25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects","volume":"26","author":"Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"RR-4","key":"key\n\t\t\t\t20180328171152_CIT246C27","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"key\n\t\t\t\t20180328171152_CIT246C28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0b013e31826ebb5c","article-title":"Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers","volume":"61","author":"Huang","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328171152_CIT246C29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/infdis\/jir246","article-title":"Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania","volume":"204","author":"Liu","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1023\/A:1007696530440","article-title":"Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985\u20131997. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA)","volume":"16","author":"Thiebaut","year":"2000","journal-title":"Eur J Epidemiol"},{"key":"key\n\t\t\t\t20180328171152_CIT246C31","first-page":"211","article-title":"Malnutrition and the severity of lung disease in adults with pulmonary tuberculosis in Malawi","volume":"8","author":"Van Lettow","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1590\/S1413-86702004000300004","article-title":"Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis","volume":"8","author":"Pedral-Sampaio","year":"2004","journal-title":"Braz J Infect Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","article-title":"Administration of efavirenz (600 mg\/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV","volume":"58","author":"Friedland","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328171152_CIT246C34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":"Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(13)70007-0","article-title":"Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial","volume":"13","author":"Bonnet","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328171152_CIT246C37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600 mg\/day versus efavirenz 800 mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3851\/IMP1780","article-title":"Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?","volume":"16","author":"Orrell","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328171152_CIT246C39","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328171152_CIT246C40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/01.aids.0000183519.45137.a6","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all","volume":"19","author":"Brennan-Benson","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328171152_CIT246C41","first-page":"333","article-title":"Trends in tuberculosis\u2014United States, 2010","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180328171152_CIT246C42","article-title":"WHO report 2011, global tuberculosis control","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180328171152_CIT246C43","article-title":"Interaction- Why did the FDA approve EFV 800 mg When Co-adminstered with Rifampin?","author":"Chan-Tack","journal-title":"San Diego, CA: American College of Clinical Pharmacology Annual Meeting 2012. Abstract 1385545."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/57\/4\/586\/17853744\/cit246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T22:47:25Z","timestamp":1688165245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/57\/4\/586\/347293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,16]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,16]]},"published-print":{"date-parts":[[2013,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit246","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718001324.793477362","asserted-by":"object"}]},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,8,15]]},"published":{"date-parts":[[2013,4,16]]}}}